The Progestin-Only Contraceptive Medroxyprogesterone Acetate, but Not Norethisterone Acetate, Enhances HIV-1 Vpr-Mediated Apoptosis in Human CD4+ T Cells through the Glucocorticoid Receptor

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Tomasicchio, Michele ^a   Avenant, Chanel ^a   Du Toit, Andrea ^a   Ray, Roslyn M ^a   Hapgood, Janet P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ESTROGEN RECEPTOR; GESTAGEN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHISTERONE ACETATE; PROGESTERONE; VPR PROTEIN; CONTRACEPTIVE AGENT; NORETHISTERONE;

APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; MOLECULAR INTERACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL DEPLETION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; SIGNAL TRANSDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CONTRACEPTIVE AGENTS, FEMALE; DEXAMETHASONE; GENE EXPRESSION REGULATION; GENE PRODUCTS, VPR; HIV-1; HUMANS; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; MOLECULAR SEQUENCE DATA; NORETHINDRONE; PROGESTERONE; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84877022987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062895     Document Type: Article

References (120)

1. WHO website. Global summary of the AIDS epidemic 2011. Available: http://www.who.int/hiv/data/en/. Accessed 2012 Sep 16.
2. Gouws E, Stanecki KA, Lyerla R, Ghys PD, (2008) The epidemiology of HIV infection among young people aged 15-24 years in Southern Africa. Aids 22Suppl 4: S5-16.
3. WHO website. Sub-Saharan Africa HIV/AIDS data and statistics 2011. Available: http://www.who.int/hiv/data/en/. Accessed 2012 Sep 16.
4. Gray RS, Hubacher JD, van Leeuwen D, de Vries RW, Bekinska F, et al. (2012) Correspondence: Use of hormonal contraceptives and risk of HIV-1 transmission. The Lancet infectious diseases 12: 507-511.
5. Heffron R, Donnell D, Rees H, Celum C, Mugo N, et al. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 12: 19-26.
6. Hel Z, Stringer E, Mestecky J, (2010) Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 31: 79-97.
7. Lavreys L, Baeten JM, Kreiss JK, Richardson BA, Chohan BH, et al. (2004) Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis 189: 303-311.
8. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, et al. (2010) Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. Aids 24: 1778-1781.
9. Morrison CS, Chen PL, Nankya I, Rinaldi A, Van Der Pol B, et al. (2011) Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 57: 157-164.
10. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, et al. (2012) Hormonal contraception and the risk of HIV acquisition among women in South Africa. Aids 26: 497-504.
11. Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, et al. (2009) Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. Aids 23Suppl 1: S69-77.
12. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, et al. (2007) A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 197: 144 e141-148.
13. Stringer EM, Levy J, Sinkala M, Chi BH, Matongo I, et al. (2009) HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. Aids 23: 1377-1382.
14. Wand H, Ramjee G, (2012) The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. Aids 26: 375-380.
15. WHO website. Hormonal contraception and HIV-1. Available: whqlibdoc.who.int/hq/2012/WHO_RHR_12.08_eng.pdf. Accessed 2012 Sep 16.
16. FHI 360 website. Expanding access to injectable contraception. Available: http://www.fhi360.org/resource/expanding-access-injectable-contraception. Accessed 2012 Sep 16.
17. Morrison CS, Nanda K, (2012) Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 12: 2-3.
18. Department of Health MRC website. South Africa demographic and health survey 2003. Available: http://www.measuredhs.com/pubs/pdf/FR206/FR206.pdf. Accessed 2012 Sep 16.
19. Heffron R, Chao A, Mwinga A, Sinyangwe S, Sinyama A, et al. (2011) High prevalent and incident HIV-1 and herpes simplex virus 2 infection among male migrant and non-migrant sugar farm workers in Zambia. Sex Transm Infect 87: 283-288.
20. Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, et al. (2006) Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database Syst Rev: CD005214.
21. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, et al. (2007) Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 75: 461-467.
22. Myer L, Denny L, Wright TC, Kuhn L, (2007) Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 36: 166-174.
23. Mostad SB, Kreiss JK, Ryncarz AJ, Mandaliya K, Chohan B, et al. (2000) Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis 181: 58-63.
24. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, et al. (1997) Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 350: 922-927.
25. Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, et al. (2004) The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS 18: 205-209.
26. Morrison CS, Bright P, Wong EL, Kwok C, Yacobson I, et al. (2004) Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm Dis 31: 561-567.
27. Watts DH, Park JG, Cohn SE, Yu S, Hitti J, et al. (2008) Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 77: 84-90.
28. Kumwenda NI, Kumwenda J, Kafulafula G, Makanani B, Taulo F, et al. (2008) HIV-1 incidence among women of reproductive age in Malawi. Int J STD AIDS 19: 339-341.
29. Africander D, Verhoog N, Hapgood JP, (2011) Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 76: 636-652.
30. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. (2012) Progestogens Used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev In press.
31. Hapgood JP, Koubovec D, Louw A, Africander D, (2004) Not all progestins are the same: implications for usage. Trends Pharmacol Sci 25: 554-557.
32. Hadley KE, Louw A, Hapgood JP, (2011) Differential nuclear localisation and promoter occupancy play a role in glucocorticoid receptor ligand-specific transcriptional responses. Steroids 76: 1176-1184.
33. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP, (2005) Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242: 23-32.
34. Ronacher K, Hadley K, Avenant C, Stubsrud E, Simons SS Jr, et al. (2009) Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction. Mol Cell Endocrinol 299: 219-231.
35. Herold MJ, McPherson KG, Reichardt HM, (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63: 60-72.
36. Zhou J, Cidlowski JA, (2005) The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 70: 407-417.
37. Kleynhans L, Du Plessis N, Allie N, Jacobs M, Kidd M, et al. (2013) The contraceptive depo medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with M. Tuberculosis. Infect Immun In press.
38. Vicetti Miguel RD, Hendricks RL, Aguirre AJ, Melan MA, Harvey SA, et al. (2012) Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. J Immunol 189: 3449-3461.
39. Genesca M, Li J, Fritts L, Chohan P, Bost K, et al. (2007) Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239. J Med Primatol 36: 266-275.
40. Trunova N, Tsai L, Tung S, Schneider E, Harouse J, et al. (2006) Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 352: 169-177.
41. Mallmann P, Dietrich K, Krebs D, (1990) Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients. Methods Find Exp Clin Pharmacol 12: 699-706.
42. Naglieri E, Lopez M, Lelli G, Morelli F, Amodio A, et al. (2002) Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res 22: 3045-3051.
43. Scambia G, Panici PB, Maccio A, Castelli P, Serri F, et al. (1988) Effects of antiestrogen and progestin on immune functions in breast cancer patients. Cancer 61: 2214-2218.
44. Yamashita J, Hideshima T, Shirakusa T, Ogawa M, (1996) Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma. Cancer 78: 2346-2352.
45. Majumder MS, Mohiduzzaman M, Ahmad K, (1987) Immunocompetence of marginally nourished women on hormonal contraceptives. Nutr Rep Int 36: 1285-1290.
46. Ghanem KG, Shah N, Klein RS, Mayer KH, Sobel JD, et al. (2005) Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 191: 358-366.
47. Huijbregts RP, Helton ES, Michel KG, Sabbaj S, Richter HE, et al. (2013) Hormonal Contraception and HIV-1 Infection: Medroxyprogesterone Acetate Suppresses Innate and Adaptive Immune Mechanisms. Endocrinology 154: 1282-95.
48. Hapgood J (2013) Immunosuppressive biological mechanisms support reassessment of usage of the injectable contraceptive medroxyprogesterone acetate. Endocrinology In press.
49. Bouman A, Heineman MJ, Faas MM, (2005) Sex hormones and the immune response in humans. Hum Reprod Update 11: 411-423.
50. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L, (2005) Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 206: 306-335.
51. Alimonti JB, Ball TB, Fowke KR, (2003) Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 84: 1649-1661.
52. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F, (2000) T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 1: 285-289.
53. Kogan M, Rappaport J, (2011) HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 8: 25.
54. Somasundaran M, Sharkey M, Brichacek B, Luzuriaga K, Emerman M, et al. (2002) Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A 99: 9503-9508.
55. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, et al. (2003) Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest 111: 1547-1554.
56. Levy DN, Refaeli Y, MacGregor RR, Weiner DB, (1994) Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 91: 10873-10877.
57. Piller SC, Jans P, Gage PW, Jans DA, (1998) Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc Natl Acad Sci U S A 95: 4595-4600.
58. Tungaturthi PK, Sawaya BE, Singh SP, Tomkowicz B, Ayyavoo V, et al. (2003) Role of HIV-1 Vpr in AIDS pathogenesis: relevance and implications of intravirion, intracellular and free Vpr. Biomed Pharmacother 57: 20-24.
59. Garg H, Mohl J, Joshi A, (2012) HIV-1 induced bystander apoptosis. Viruses 4: 3020-3043.
60. Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, et al. (2002) HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 302: 95-105.
61. Arunagiri C, Macreadie I, Hewish D, Azad A, (1997) A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes. Apoptosis 2: 69-76.
62. Borgne-Sanchez A, Dupont S, Langonne A, Baux L, Lecoeur H, et al. (2007) Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell Death Differ 14: 422-435.
63. Coeytaux E, Coulaud D, Le Cam E, Danos O, Kichler A, (2003) The cationic amphipathic alpha-helix of HIV-1 viral protein R (Vpr) binds to nucleic acids, permeabilizes membranes, and efficiently transfects cells. J Biol Chem 278: 18110-18116.
64. Henklein P, Bruns K, Sherman MP, Tessmer U, Licha K, et al. (2000) Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J Biol Chem 275: 32016-32026.
65. Arokium H, Kamata M, Chen I, (2009) Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human T cells. J Virol 83: 11283-11297.
66. Lu YL, Spearman P, Ratner L, (1993) Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol 67: 6542-6550.
67. Patel CA, Mukhtar M, Pomerantz RJ, (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74: 9717-9726.
68. Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, et al. (2010) HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. Aids 24: 1107-1119.
69. Andersen JL, Le Rouzic E, Planelles V, (2008) HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 85: 2-10.
70. Hapgood JP, Tomasicchio M, (2010) Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis. Arch Virol 155: 1009-1019.
71. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, et al. (1999) The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med 189: 51-62.
72. Muthumani K, Premkumar A, (2005) Human immunodeficiency virus type 1 (HIV-1) Vpr- regulated cell death: insights into mechanism. Cell Death Differ 1: 962-970.
73. Sherman MP, DeNoronha CM, Pearce D, Greene WC, (2000) Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J Virol 74: 8159-8165.
74. Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, et al. (1997) HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nature medicine. 3: 1117-1123.
75. Sambrook J, Russell DW (2001) Molecular Cloning, a laboratory manual. Third Edition. Cold Springs Harbour Press, New York.
76. Thorsby E, Bratlie A (1970) A rapid method for preparation of pure lymphocyte suspensions. In: Terasaki PI, editor. Histocompatibility Testing: Munksgaard, Copenhagen. 665-666.
77. Sanford-Burnham Medical Research Institute website. Available: http://sr.burnham.org/sr/homepage/proteomics/solndig.html. Accessed 2011 May 10.
78. Jochmann R, Thurau M, Jung S, Hofmann C, Naschberger E, et al. (2009) O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol 83: 3704-3718.
79. Ghosh SK, Fultz PN, Keddie E, Saag MS, Sharp PM, et al. (1993) A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. Virology 194: 858-864.
80. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, et al. (2004) Dual HIV-1 infection associated with rapid disease progression. Lancet 363: 619-622.
81. Reed LJM, (1938) H (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27: 493-497.
82. Boutwell CL, Rowley CF, Essex M, (2009) Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol 83: 2460-2468.
83. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, et al. (2003) Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 88: 2309-2317.
84. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
85. Cuzick J, (1985) A Wilcoxon-type test for trend. Stat Med 4: 87-90.
86. Hiroi M, Stanczyk FZ, Goebelsmann U, Brenner PF, Lumkin ME, et al. (1975) Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration. Steroids 26: 373-386.
87. Kirton KT, Cornette JC, (1974) Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera). Contraception 10: 39-45.
88. Mishell DR Jr, (1996) Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 41: 381-390.
89. Shrimanker K, Saxena BN, Fotherby K, (1978) A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem 9: 359-363.
90. Fotherby K, Howard G, Shrimanker K, Elder M, Bye PG, (1978) Plasma levels of norethisterone after single and multiple injections of norethisterone oenanthate. Contraception 18: 1-6.
91. Goebelsmann U, Stanczyk FZ, Brenner PF, Goebelsmann AE, Gentzschein EK, et al. (1979) Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone. Contraception 19: 283-313.
92. Howard G, Warren RJ, Fotherby K, (1975) Plasma levels of norethisterone in women receiving norethisterone oenanthate intramuscularly. Contraception 12: 45-52.
93. Buckingham JC, (2006) Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 147Suppl 1: S258-268.
94. Kontula K, Paavonen T, Luukkainen T, Andersson LC, (1983) Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 32: 1511-1518.
95. Koubovec D, Vanden Berghe W, Vermeulen L, Haegeman G, Hapgood JP, (2004) Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 221: 75-85.
96. Bandera A, Ferrario G, Saresella M, Marventano I, Soria A, et al. (2010) CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals. PloS one 5: e10788.
97. Busca A, Saxena M, Kumar A, (2012) Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem 287: 15118-15133.
98. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, et al. (2002) HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 277: 37820-37831.
99. Roumier T, Vieira HL, Castedo M, Ferri KF, Boya P, et al. (2002) The C-terminal moiety of HIV-1 Vpr induces cell death via a caspase-independent mitochondrial pathway. Cell Death Differ 9: 1212-1219.
100. Stewart SA, Poon B, Song JY, Chen IS, (2000) Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 74: 3105-3111.
101. Africander A, Louw R, Hapgood J (2013) Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy. Biochem Biophys Res Comm In press.
102. Pronsato L, Boland R, Milanesi L, (2012) Testosterone exerts antiapoptotic effects against H2O2 in C2C12 skeletal muscle cells through the apoptotic intrinsic pathway. J Endocrinol 212: 371-381.
103. Tang F, Kokontis J, Lin Y, Liao S, Lin A, et al. (2009) Androgen via p21 inhibits tumor necrosis factor alpha-induced JNK activation and apoptosis. J Biol Chem 284: 32353-32358.
104. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, et al. (2005) Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 97: 1746-1759.
105. Vasconsuelo A, Milanesi L, Boland R, (2010) Participation of HSP27 in the antiapoptotic action of 17beta-estradiol in skeletal muscle cells. Cell Stress Chaperones 15: 183-192.
106. Gagliardo R, Chanez P, Vignola AM, Bousquet J, Vachier I, et al. (2000) Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma. Am J Respir Crit Care Med 162: 7-13.
107. Miura R, Nakamura K, Miura D, Miura A, Hisamatsu K, et al. (2006) Aldosterone synthesis and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Sci 102: 288-295.
108. Hoshino S, Sun B, Konishi M, Shimura M, Segawa T, et al. (2007) Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Res Hum Retroviruses 23: 391-397.
109. Mishra S, Mishra JP, Kumar A, (2007) Activation of JNK-dependent pathway is required for HIV viral protein R-induced apoptosis in human monocytic cells: involvement of antiapoptotic BCL2 and c-IAP1 genes. J Biol Chem 282: 4288-4300.
110. Conti L, Matarrese P, Varano B, Gauzzi MC, Sato A, et al. (2000) Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells. J Immunol 165: 3293-3300.
111. Chen M, Elder RT, Yu M, O'Gorman MG, Selig L, et al. (1999) Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast. J Virol 73: 3236-3245.
112. Di Marzio P, Choe S, Ebright M, Knoblauch R, Landau NR, (1995) Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol 69: 7909-7916.
113. Mahalingam S, Collman RG, Patel M, Monken CE, Srinivasan A, (1995) Functional analysis of HIV-1 Vpr: identification of determinants essential for subcellular localization. Virology 212: 331-339.
114. Mann CL, Hughes FM Jr, Cidlowski JA, (2000) Delineation of the signaling pathways involved in glucocorticoid-induced and spontaneous apoptosis of rat thymocytes. Endocrinology 141: 528-538.
115. Wang Z, Malone MH, He H, McColl KS, Distelhorst CW, (2003) Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J Biol Chem 278: 23861-23867.
116. Yovel G, Shakhar K, Ben-Eliyahu S, (2001) The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol 81: 254-262.
117. Burleson MH, Malarkey WB, Cacioppo JT, Poehlmann KM, Kiecolt-Glaser JK, et al. (1998) Postmenopausal hormone replacement: effects on autonomic, neuroendocrine, and immune reactivity to brief psychological stressors. Psychosom Med 60: 17-25.
118. Yang JH, Chen CD, Wu MY, Chao KH, Yang YS, et al. (2000) Hormone replacement therapy reverses the decrease in natural killer cytotoxicity but does not reverse the decreases in the T-cell subpopulation or interferon-gamma production in postmenopausal women. Fertil Steril 74: 261-267.
119. Stanczyk FZ, (2002) Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 3: 211-224.
120. Sibeko S, Baxter C, Yende N, Karim QA, Karim SS, (2011) Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol 118: 895-904.